TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update
February 26 2021 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held on Tuesday, March 2, 2021 at 8:30 AM
ET to discuss results for the fourth quarter and year-end 2020 and
provide a business outlook for 2021. Michael S. Weiss, Executive
Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics Fourth Quarter and Year End 2020
Update Call. A live webcast of this presentation will be available
on the Events page, located within the Investors & Media
section, of the Company's website at www.tgtherapeutics.com. An
audio recording of the conference call will also be available for
replay at www.tgtherapeutics.com, for a period of 30 days after the
call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a fully-integrated, commercial stage
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. In addition to an active research pipeline
including five investigational medicines across these therapeutic
areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ™ (umbralisib), for the
treatment of adult patients with relapsed/refractory marginal zone
lymphoma who have received at least one prior anti-CD20-based
regimen and relapsed/refractory follicular lymphoma who have
received at least three prior lines of systemic therapies.
Currently, the Company has two programs in Phase 3 development for
the treatment of patients with relapsing forms of multiple
sclerosis (RMS) and patients with chronic lymphocytic leukemia
(CLL) and several investigational medicines in Phase 1 clinical
development. For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.UKONIQ™ is a
registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations Email:
ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations: Email:
media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024